Risorius Co., Ltd. is a deep learning-based neurotechnology company advancing the quantification and personalization of care in psychiatry and neurology. We develop clinically actionable, EEG-based predictive biomarkers that support neuropsychiatric diagnosis, prognosis stratification, and precision drug prescription for both clinical practice and pharmaceutical development.
Leveraging proprietary EEG preprocessing models and end-to-end analysis pipelines powered by deep learning and explainable AI (xAI), Risorius transforms complex brain signals into interpretable insights that align with real-world clinical decision-making. Our platform is designed for scalability and multimodal expansion, with ongoing integration of MRI, polysomnography (PSG), and electronic health record (EHR) data to enable comprehensive brain-state characterization across disorders and treatment stages.
By bridging neuroscience, artificial intelligence, and clinical psychiatry, Risorius aims to redefine how brain data is quantified, interpreted, and applied—accelerating the transition toward objective, personalized neuropsychiatric care.
Developing EEG-based AI markers to quantify brain-level effects of digital mental health interventions
Partner seeks Consortium/Coordinator
DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
Contributing a practical EEG-AI NAM use case to support ERA coordination, training, and harmonised openness for NAM uptake
Partner seeks Consortium/Coordinator
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices